InDex Pharmaceuticals Holding
0.357 SEK +2.59%InDex Pharmaceuticals is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late-stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent-protected discovery stage substances, so-called DNA-based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm.
Read moreAnalyst
Latest videos
Financial calendar
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Linc AB | 13.1 % | 13.1 % |
Fjärde AP-Fonden | 9.8 % | 9.8 % |
Premium
This content is for our Premium customers only.
Index Pharmaceuticals: InDex Pharmaceuticals brings forward the publication of the interim report for Q1 2024
Index Pharmaceuticals: InDex Pharmaceuticals ger en företagsuppdatering
Join Inderes community
Don't miss out - create an account and get all the possible benefits